A compelling need exists for a more reliable risk evaluation of natalizumab- associated progressive multifocal leukoencephalopathy (PML). A new report proposes a refined protocol that uses updated patient-based data and cumulative risk evaluation to provide an improved assessment of the annual risk of PML for patients positive for JC virus.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Biogen. TYSABRI® (natalizumab). Biogen https://medinfo.biogen.com/secure/pmlresource (2016).
Hoepner, R. et al. Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy. Mult. Scler. 23, 830–835 (2017).
Ho, P. R. et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 16, 925–933 (2017).
Bloomgren, G. et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366, 1870–1880 (2012).
Plavina, T. et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann. Neurol. 76, 802–812 (2014).
McGuigan, C. et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J. Neurol. Neurosurg. Psychiatry 87, 117–125 (2016).
Borchardt, J. & Berger, J. R. Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy. Mult. Scler. Relat. Disord. 8, 145–150 (2016).
Kalincik, T. et al. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurol. 16, 271–281 (2017).
Schwab, N. et al. Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification. Neurology 88, 1197–1205 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
K.P. received speaker honoraria and travel funding from Bayer Schering Pharma, Biogen Idec and Novartis. R.G. serves on scientific advisory boards for Bayer Schering Pharma, Biogen Idec, Novartis and Teva Pharmaceutical Industries Ltd; has received speaker honoraria from Bayer Schering Pharma, Biogen Idec, Novartis and Teva Pharmaceutical Industries Ltd; serves as editor for Therapeutic Advances in Neurological Disorders and on the editorial boards of Experimental Neurology and the Journal of Neuroimmunology; and receives research support from Bayer Schering Pharma, Biogen Idec, Genzyme, Merck Serono, Novartis and Teva Pharmaceutical Industries Ltd, none related to this manuscript.
Rights and permissions
About this article
Cite this article
Pitarokoili, K., Gold, R. Progressive multifocal leukoencephalopathy risk stratification. Nat Rev Neurol 13, 710–712 (2017). https://doi.org/10.1038/nrneurol.2017.161
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2017.161
